Antiviral Activity of Hederasaponin B from Hedera helix against Enterovirus 71 Subgenotypes C3 and C4a.
- Author:
Jaehyoung SONG
1
;
Sang Gu YEO
;
Eun Hye HONG
;
Bo Ra LEE
;
Jin Won KIM
;
Jeonghoon KIM
;
Hyeongun JEONG
;
Yongsoo KWON
;
Hyunpyo KIM
;
Sangwon LEE
;
Jae Hak PARK
;
Hyun Jeong KO
Author Information
1. Division of Vaccine Research, Center for Infectious Diseases, National Institute of Health, Korea Centers for Diseases Control and Prevention, Osong 363-951, Republic of Korea.
- Publication Type:Original Article
- Keywords:
Enterovirus 71;
Antiviral activity;
Hederasaponin B;
Hedera helix;
Hand foot and mouth disease
- MeSH:
Blotting, Western;
Capsid Proteins;
Enterovirus*;
Ethanol;
Hand, Foot and Mouth Disease;
Hedera*;
Vero Cells
- From:Biomolecules & Therapeutics
2014;22(1):41-46
- CountryRepublic of Korea
- Language:English
-
Abstract:
Enterovirus 71 (EV71) is the predominant cause of hand, foot and mouth disease (HFMD). The antiviral activity of hederasaponin B from Hedera helix against EV71 subgenotypes C3 and C4a was evaluated in vero cells. In the current study, the antiviral activity of hederasaponin B against EV71 C3 and C4a was determined by cytopathic effect (CPE) reduction method and western blot assay. Our results demonstrated that hederasaponin B and 30% ethanol extract of Hedera helix containing hederasaponin B showed significant antiviral activity against EV71 subgenotypes C3 and C4a by reducing the formation of a visible CPE. Hederasaponin B also inhibited the viral VP2 protein expression, suggesting the inhibition of viral capsid protein synthesis.These results suggest that hederasaponin B and Hedera helix extract containing hederasaponin B can be novel drug candidates with broad-spectrum antiviral activity against various subgenotypes of EV71.
